Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma
Authors:
- 1 July 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 223 (1) , 9-18
Abstract
Whether patients with positive SLNB should undergo complete lymph node dissection (CLND) is an important unanswered clinical question. Patients diagnosed with positive SLNB at a melanoma referral center from 1991 to 2013 were studied. Outcomes of patients who underwent CLND were compared with those who did not undergo immediate CLND (observation [OBS] group). There were 471 patients who had positive SLNB; 375 (79.6%) in the CLND group and 96 (20.4%) in the OBS group. The groups were similar except that the CLND group was younger and had more sentinel nodes removed. Five-year nodal recurrence-free survival was significantly better in the CLND group compared with the OBS group (93.1% vs 84.4%; p = 0.005). However, 5-year (66.4% vs 55.2%) and 10-year (59.5% vs 45.0%) distant metastasis-free survival rates were not significantly different (p = 0.061). The CLND group's melanoma-specific survival (MSS) rate was superior to that of the OBS group; 5-year MSS rates were 73.7% vs 65.5% and 10-year MSS rates were 66.8% vs 48.3% (p = 0.015). On multivariate analysis, CLND was associated with improved MSS (hazard ratio = 0.60; 95% CI, 0.40-0.89; p = 0.011) and lower nodal recurrence (hazard ratio = 0.46; 95% CI, 0.24-0.86; p = 0.016). Increased Breslow thickness, older age, ulceration, and trunk melanoma were all associated with worse outcomes. On subgroup analysis, the following factors were associated with better outcomes from CLND: male sex, nonulcerated primary, intermediate thickness, Clark level IV or lower extremity tumors. Treatment of positive SLNB with CLND was associated with improved MSS and nodal recurrence rates. Follow-up beyond 5 years was needed to see a significant difference in MSS rates.Keywords
This publication has 37 references indexed in Scilit:
- Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissectionBritish Journal of Surgery, 2012
- Cost-effectiveness of Adding FDG-PET or CT to the Diagnostic Work-up of Patients With Stage III MelanomaAnnals of Surgery, 2012
- Validation of Statistical Predictive Models Meant to Select Melanoma Patients for Sentinel Lymph Node BiopsyAnnals of Surgical Oncology, 2011
- Sentinel node biopsy in melanoma: Technical considerations of the procedure as performed at the john wayne cancer instituteJournal of Surgical Oncology, 2010
- Early (sentinel lymph node biopsy‐guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastasesCancer, 2010
- The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2–pT3)Annals of Surgical Oncology, 2008
- How Should We View the Results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?Annals of Surgical Oncology, 2008
- Sentinel-Node Biopsy or Nodal Observation in MelanomaNew England Journal of Medicine, 2006
- Melanoma Patients with Positive Sentinel Nodes Who Did Not Undergo Completion Lymphadenectomy: A Multi-Institutional StudyAnnals of Surgical Oncology, 2006
- Long-Term Results of a Multi-Institutional Randomized Trial Comparing Prognostic Factors and Surgical Results for Intermediate Thickness Melanomas (1.0 to 4.0 mm)Annals of Surgical Oncology, 2000